In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status

Carlos G Santos-Gallego; Harriette G C Van Spall

doi:10.7326/ACPJ202106150-068

In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status

Ann Intern Med. 2021 Jun;174(6):JC68. doi: 10.7326/ACPJ202106150-068. Epub 2021 Jun 1.

Authors

Carlos G Santos-Gallego¹, Harriette G C Van Spall²

Affiliations

¹ Mount Sinai Hospital, New York, New York, USA (C.G.S.).
² McMaster University, Hamilton, Ontario, Canada (H.G.V.).

PMID: 34058113
DOI: 10.7326/ACPJ202106150-068

Abstract

Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation. 2021;143:310-21. 33095032.

Publication types

Comment

MeSH terms

Benzhydryl Compounds
Glucosides / therapeutic use
Heart Failure* / drug therapy
Humans
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy
Stroke Volume

Substances

Benzhydryl Compounds
Glucosides
empagliflozin